Sub analysis of ARISTOTLE trial for Eliquis in Stroke Prevention - BMS/Pfizer

Bristol-Myers Squibb Company and Pfizer Inc. have announced results of a pre-specified subanalysis of the Phase III ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the efficacy and safety of Eliquis (apixaban) compared to warfarin for reducing the Risk of Stroke or Systemic Embolism in patients with nonvalvular atrial fibrillation (NVAF).

This subanalysis found consistent results across age groups for reducing the risk of stroke and systemic embolism and reducing the risk of all-cause death with fewer bleeding events. Owing to the higher risk at older age (age 75 and older), the absolute benefit to patients with NVAF was greater with Eliquis in the older population. These data were published in the European Heart Journal.

See - "Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial" - Sigrun Halvorsen, Dan Atar, Hongqiu Yang, Raffaele De Caterina, Cetin Erol, David Garcia, Christopher B. Granger, Michael Hanna, Claes Held, Steen Husted, Elaine M. Hylek, Petr Jansky, Renato D. Lopes, Witold Ruzyllo, Laine Thomas and Lars Wallentin. - Eur Heart J (2014) doi: 10.1093/eurheartj/ehu046 -First published online: February 20, 2014.